Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
71.48
-0.81 (-1.12%)
Jun 5, 2026, 4:00 PM EDT - Market closed
Cytokinetics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 105.82 | 88.04 | 18.47 | 7.53 | 94.59 | 70.43 | |
Revenue Growth (YoY) | 450.60% | 376.56% | 145.34% | -92.04% | 34.30% | 26.15% |
Cost of Revenue | 411.71 | 416.03 | 339.41 | 330.12 | 240.81 | 159.94 |
Gross Profit | -305.9 | -327.99 | -320.93 | -322.59 | -146.23 | -89.51 |
Selling, General & Admin | 331.8 | 284.27 | 215.31 | 173.61 | 177.98 | 96.8 |
Research & Development | 411.71 | 416.03 | 339.41 | 330.12 | 240.81 | 159.94 |
Total Operating Expenses | 743.51 | 700.3 | 554.72 | 503.74 | 418.79 | 256.74 |
Operating Income | -640.25 | -612.26 | -536.25 | -496.21 | -324.2 | -186.31 |
Interest Income | 45.74 | 48.42 | 51.53 | 27.63 | 11.34 | 0.33 |
Interest Expense | -114.26 | -103.87 | -86.51 | -57.67 | -76.1 | -29.33 |
Other Non-Operating Income (Expense) | -120.85 | -117.25 | -18.3 | - | - | - |
Total Non-Operating Income (Expense) | -189.37 | -172.7 | -53.28 | -30.04 | -64.75 | -29 |
Pretax Income | -829.61 | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 |
Net Income | -829.61 | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 |
Net Income to Common | -829.61 | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 |
Shares Outstanding (Basic) | 121 | 120 | 112 | 97 | 90 | 77 |
Shares Outstanding (Diluted) | 121 | 120 | 112 | 97 | 90 | 77 |
Shares Change (YoY) | 4.67% | 7.26% | 16.01% | 7.46% | 16.83% | 19.16% |
EPS (Basic) | -6.84 | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 |
EPS (Diluted) | -6.84 | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 |
Shares Outstanding | 123.27 | 122.94 | 118.21 | 101.64 | 94.83 | 84.8 |
Free Cash Flow | -548.92 | -534.82 | -399.8 | -415.75 | -310.85 | -191.39 |
Free Cash Flow Per Share | -4.53 | -4.45 | -3.57 | -4.31 | -3.46 | -2.49 |
Gross Margin | -289.08% | -372.55% | -1737.22% | -4284.10% | -154.59% | -127.09% |
Operating Margin | -605.06% | -695.44% | -2902.72% | -6589.71% | -342.75% | -264.54% |
Profit Margin | -784.02% | -891.60% | -3191.11% | -6988.63% | -411.21% | -305.72% |
FCF Margin | -518.76% | -607.48% | -2164.10% | -5521.24% | -328.64% | -271.76% |
EBITDA | -629.04 | -602.13 | -526.72 | -484.31 | -318.39 | -184.04 |
EBITDA Margin | -594.47% | -683.94% | -2851.13% | -6431.78% | -336.61% | -261.31% |
EBIT | -640.25 | -612.26 | -536.25 | -496.21 | -324.2 | -186.31 |
EBIT Margin | -605.06% | -695.44% | -2902.72% | -6589.71% | -342.75% | -264.54% |